KLRA (Kailera Therapeutics) Accounts Payable: $7.53 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Accounts Payable?

Kailera Therapeutics KLRA +2.24% 11 Accounts Payable is $7.53 Mil as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Kailera Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was $7.53 Mil.

Kailera Therapeutics's quarterly Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2024 ($2.01 Mil) and increased from Dec. 2024 ($2.01 Mil) to Dec. 2025 ($7.53 Mil).

Kailera Therapeutics's annual Accounts Payable increased from . 20 ($0.00 Mil) to Dec. 2024 ($2.01 Mil) and increased from Dec. 2024 ($2.01 Mil) to Dec. 2025 ($7.53 Mil).

Kailera Therapeutics Accounts Payable Related Terms

Kailera Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Accounts Payable Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Accounts Payable
2.01 7.53

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
Accounts Payable 2.01 7.53
KLRA
11GF Score
Kailera Therapeutics Inc KLRA
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $7.53 Mil mean?
Kailera Therapeutics (KLRA) has a Accounts Payable of $7.53 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Kailera Therapeutics and its competitors.
Is Kailera Therapeutics' Accounts Payable too high?
Kailera Therapeutics' current Accounts Payable is $7.53 Mil. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Accounts Payable compare to VCEL and NUVB?
Kailera Therapeutics' Accounts Payable of $7.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current Accounts Payable is $7.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Accounts Payable of $7.53 Mil. The current Accounts Payable is $7.53 Mil. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Accounts Payable is $7.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price